LUCD

Over the past six months (March 2026 - September 2026), Lucid Diagnostics experienced several stock-impacting events. In April 2026, the company closed an $18 million underwritten stock sale. May 2026 saw a director purchase 245,000 shares, and the company reported narrowing its loss while extending its cash runway into 2027. In June 2026, Lucid Diagnostics boosted its authorized shares to 400 million and re-elected directors. August 2026 brought a commercial coverage policy for its EsoGuard® Esophageal DNA Test from Concert, adopted by multiple client health plans. The company also provided a business update and reported its second-quarter 2026 financial results, recognizing $1.5 million in revenue from 2,770 EsoGuard tests but posting a wider loss for the quarter. PAVmed, Lucid's parent company, also reported its Q2 2026 results. In September 2026, Lucid Diagnostics announced advancements in multiple EsoGuard® and EsoCheck® payment, billing, and coding pathways, including a Medicare Advisory Panel recommendation to maintain EsoGuard's original gapfill payment basis and the AMA CPT Editorial Panel's approval of a new Category III CPT code. As of September 11, 2026, the stock price was $0.78 per share, representing a 24.17% decline from $1.03 per share on September 12, 2025, with a 52-week high of $1.63 and a 52-week low of $0.75.